勘误：HER2阳性乳腺癌脑转移的危险因素及预后：一项来自中国的单机构回顾性分析。
Erratum: Risk factors of brain metastasis and prognosis in HER2-positive breast cancer: A single-institution retrospective analysis from China.
出版信息
Front Oncol. 2022 Sep 20;12:1027199. doi: 10.3389/fonc.2022.1027199. eCollection 2022.
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.905065.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2022.905065。]
相似文献
1
Erratum: Risk factors of brain metastasis and prognosis in HER2-positive breast cancer: A single-institution retrospective analysis from China.勘误：HER2阳性乳腺癌脑转移的危险因素及预后：一项来自中国的单机构回顾性分析。
Front Oncol. 2022 Sep 20;12:1027199. doi: 10.3389/fonc.2022.1027199. eCollection 2022.
2
Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China.HER2阳性乳腺癌脑转移的危险因素及预后：来自中国的单机构回顾性分析
Front Oncol. 2022 Jun 27;12:905065. doi: 10.3389/fonc.2022.905065. eCollection 2022.
3
Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.勘误：ANKRD44基因沉默：在人表皮生长因子受体2（Her2）样乳腺癌曲妥珠单抗耐药中的潜在作用。
Front Oncol. 2019 Jul 18;9:709. doi: 10.3389/fonc.2019.00709. eCollection 2019.
4
Erratum: The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis.勘误：去泛素化酶UCHL1通过促进游离脂肪酸合成诱导HER2阳性乳腺癌对多柔比星产生耐药性。
Front Oncol. 2021 Apr 14;11:687249. doi: 10.3389/fonc.2021.687249. eCollection 2021.
5
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.勘误：HER2阳性乳腺癌新辅助曲妥珠单抗化疗后基线和残留肿瘤中的PAM50亚型：来自单一机构的连续系列研究。
Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019.
6
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.HER2阳性乳腺癌发生脑转移患者的预后因素：一项多中心回顾性分析。
Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21.
7
Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.探索HER2阳性转移性乳腺癌的预后因素：一项在瑞士一家大型医院进行的回顾性队列研究。
Swiss Med Wkly. 2016 Dec 19;146:w14393. doi: 10.4414/smw.2016.14393. eCollection 2016.
8
New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.激素受体阳性、HER2 阴性乳腺癌患者首发转移部位对生存影响的新认识：271 例患者的多中心研究。
BMC Cancer. 2021 Apr 29;21(1):476. doi: 10.1186/s12885-021-08219-3.
9
Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.真实世界中转移性乳腺癌患者的脑转移：一项单机构、为期12年随访的回顾性研究
Breast Cancer Res Treat. 2017 Feb;162(1):169-179. doi: 10.1007/s10549-017-4107-x. Epub 2017 Jan 13.
10
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.基质金属蛋白酶11和CD2作为激素受体阴性、人表皮生长因子受体2阳性乳腺癌的新型预后因素。
Breast Cancer Res Treat. 2017 Jul;164(1):41-56. doi: 10.1007/s10549-017-4234-4. Epub 2017 Apr 13.
Zotero 插件